Abstract
The von Hippel–Lindau tumor suppressor pVHL regulates the stability of hypoxia-inducible factors (HIF)-1 and -2, oxygen-sensitive basic helix–loop–helix transcription factors, which mediate the hypoxic induction of angiogenic growth factors such as vascular endothelial growth factor. Loss of pVHL function results in constitutive activation of HIF-1 and HIF-2 and is associated with the development of highly vascularized tumors in multiple organs. We have used a conditional gene-targeting approach to investigate the relative contributions of HIF-1 and HIF-2 to VHL-associated vascular tumorigenesis in a mouse model of liver hemangiomas. Here we demonstrate genetically that conditional inactivation of HIF-2α suppressed the development of VHL-associated liver hemangiomas and that angiogenic gene expression in hepatocytes is predominantly regulated by HIF-2 and not by HIF-1. These findings suggest that HIF-2 is the dominant HIF in the pathogenesis of VHL-associated vascular tumors and that pharmacologic targeting of HIF-2 may be an effective strategy for their treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Biju MP, Neumann AK, Bensinger SJ, Johnson RS, Turka LA, Haase VH . (2004). Vhlh gene deletion induces Hif-1-mediated cell death in thymocytes. Mol Cell Biol 24: 9038–9047.
Bindra RS, Vasselli JR, Stearman R, Linehan WM, Klausner RD . (2002). VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res 62: 3014–3019.
Chavez JC, Baranova O, Lin J, Pichiule P . (2006). The transcriptional activator hypoxia inducible factor 2 (HIF-2/EPAS-1) regulates the oxygen-dependent expression of erythropoietin in cortical astrocytes. J Neurosci 26: 9471–9481.
Fischer A, Schumacher N, Maier M, Sendtner M, Gessler M . (2004). The Notch target genes Hey1 and Hey2 are required for embryonic vascular development. Genes Dev 18: 901–911.
Flamme I, Krieg M, Plate KH . (1998). Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF/HIF-2alpha. Am J Pathol 153: 25–29.
Gijtenbeek JM, Boots-Sprenger SH, Franke B, Wesseling P, Jeuken JW . (2005). Cyclin D1 genotype and expression in sporadic hemangioblastomas. J Neurooncol 74: 261–266.
Gruber M, Hu CJ, Johnson RS, Brown EJ, Keith B, Simon MC . (2007). Acute postnatal ablation of Hif-2alpha results in anemia. Proc Natl Acad Sci USA 104: 2301–2306.
Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J et al. (2005). Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 9: 617–628.
Haase VH, Glickman JN, Socolovsky M, Jaenisch R . (2001). Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci USA 98: 1583–1588.
Holmquist-Mengelbier L, Fredlund E, Lofstedt T, Noguera R, Navarro S, Nilsson H et al. (2006). Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 10: 413–423.
Kapitsinou PP, Haase VH . (2008). The VHL tumor suppressor and HIF: insights from genetic studies in mice. Cell Death Differ 15: 650–659.
Maher ER, Kaelin Jr WG . (1997). von Hippel-Lindau disease. Medicine (Baltimore) 76: 381–391.
McGrath FP, Gibney RG, Morris DC, Owen DA, Erb SR . (1992). Case report: multiple hepatic and pulmonary haemangioblastomas—a new manifestation of von Hippel-Lindau disease. Clin Radiol 45: 37–39.
Rankin EB, Biju MP, Liu Q, Unger TL, Rha J, Johnson RS et al. (2007). Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest 117: 1068–1077.
Rankin EB, Giaccia AJ . (2008). The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 15: 678–685.
Rankin EB, Higgins DF, Walisser JA, Johnson RS, Bradfield CA, Haase VH . (2005). Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice. Mol Cell Biol 25: 3163–3172.
Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li JL et al. (2005). Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell Biol 25: 5675–5686.
Rothhammer T, Bataille F, Spruss T, Eissner G, Bosserhoff AK . (2007). Functional implication of BMP4 expression on angiogenesis in malignant melanoma. Oncogene 26: 4158–4170.
Vortmeyer AO, Gnarra JR, Emmert-Buck MR, Katz D, Linehan WM, Oldfield EH et al. (1997). von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Hum Pathol 28: 540–543.
White P, Brestelli JE, Kaestner KH, Greenbaum LE . (2005). Identification of transcriptional networks during liver regeneration. J Biol Chem 280: 3715–3722.
Zatyka M, Da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU et al. (2002). Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res 62: 3803–3811.
Acknowledgements
This work was supported by NIH grant DK073467 and CA100787 (both to VHH), the Center for Molecular Studies in Digestive and Liver Disease (P30-DK50306) and the Penn Diabetes and Endocrinology Research Center Functional Genomics Core (P30-DK19525). EBR was supported by a fellowship grant from the American Heart Association.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).
Supplementary information
Rights and permissions
About this article
Cite this article
Rankin, E., Rha, J., Unger, T. et al. Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice. Oncogene 27, 5354–5358 (2008). https://doi.org/10.1038/onc.2008.160
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2008.160
Keywords
This article is cited by
-
HIF1α and HIF2α immunoreactivity in epithelial tissue of primary and recurrent pterygium by immunohistochemical analysis
International Ophthalmology (2023)
-
A role for spinal cord hypoxia in neurodegeneration
Cell Death & Disease (2019)
-
Hypoxia-inducible factor 2α is a negative regulator of osteoblastogenesis and bone mass accrual
Bone Research (2019)
-
WISP-1 positively regulates angiogenesis by controlling VEGF-A expression in human osteosarcoma
Cell Death & Disease (2017)
-
Cells of renin lineage express hypoxia inducible factor 2α following experimental ureteral obstruction
BMC Nephrology (2016)